Pharmacokinetics & Dosing

Dosing context matters for aspirin.

The dose used for cardiovascular prevention is not automatically the same as the dose of greatest interest in oncology. Duration of use also matters.

Dosing patterns seen in studies

• 75 to 100 mg daily — most relevant for current low-dose oncology discussion

• 325 mg daily — used in some older studies and prevention settings

• long-term use — often needed in prevention research

• adjuvant timing — post-surgery or post-chemotherapy is the main current oncology model

Why dosing matters

Low-dose aspirin is enough for platelet inhibition.

Other proposed anticancer effects may depend on duration, tissue exposure, or higher-intensity signalling effects. Even so, higher doses raise bleeding risk and do not yet have clearly superior oncology evidence.

Practical interpretation

The most practical oncology discussion point is usually low-dose aspirin.

That is where the best current balance sits between evidence and tolerability. Higher-dose use needs much more caution.

Key References

• Deng L et al. (2024). Exploring Aspirin's Potential in Cancer Prevention (aspirin's short half-life ~20 min; daily low-dose primarily targets platelet COX-1). Biomolecules 14(10):1320. https://pmc.ncbi.nlm.nih.gov/articles/PMC11498354/[^14]

• Salmond RJ et al. (2025). Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cells (mechanistic basis for low-dose platelet targeting vs high-dose nucleated cell effects). Nature 640(8060):1052–1061. https://www.nature.com/articles/s41586-025-08626-7[^17]

• Thijssen PT et al. (2023). Pharmacokinetic Study of Enteric-Coated Sustained-Release Aspirin Tablets. Drug Des Devel Ther 17:2427–2439. https://pmc.ncbi.nlm.nih.gov/articles/PMC10443535/[^41]

• Grosser N et al. (2006). Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers (enteric-coated aspirin inferior to plain aspirin for TXB2 inhibition; 20% treatment failure at 80 kg). Stroke 37(8):2153–8. https://pubmed.ncbi.nlm.nih.gov/16794200/[^42]

• Bonten TN et al. (2003). Pharmacokinetic and pharmacodynamic differences between two low-dose aspirin formulations (80 mg vs 160 mg daily; accumulation effects). Clin Pharmacokinet 42(12):1059–70. https://pubmed.ncbi.nlm.nih.gov/12959636/[^43]

• Li K et al. (2025). Long-term use of low-dose aspirin for cancer prevention (90% of cohort on 80 mg; benefits stronger after 10+ years use). Cancer Medicine 14(1). https://pmc.ncbi.nlm.nih.gov/articles/PMC12008822/[^6]

• Lip GYH et al. (2013). Low-dose aspirin use and cancer characteristics (aspirin in year prior to diagnosis → lower tumour extent, fewer metastases in CRC and lung). Int J Cancer 133(8):1911–8. https://pubmed.ncbi.nlm.nih.gov/23887604/[^44]

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form